Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English
News18 » Business
1-min read

Dr Reddy’s Q1 Profit Jumps 45% on One-time Gains, Revenue Grows Just 3%

Dr Reddy’s Laboratories stock had already closed Monday’s trading session lower by 1.9% before the quarterly results were announced. The real effect of the earnings on the stock price would only be visible on Tuesday.

Trending Desk

Updated:July 29, 2019, 6:10 PM IST
facebookTwitterskypewhatsapp
Dr Reddy’s Q1 Profit Jumps 45% on One-time Gains, Revenue Grows Just 3%
File image of Dr. Reddy's Laboratories Ltd logo. Image: Twitter
Loading...

Dr Reddy’s Laboratories announced on Monday, after market hours, that its consolidated profit after tax (PAT) for the first quarter ended June (Q1) climbed 45% year-on-year to Rs 662.80 crore compared with Rs 456.10 crore in the year-ago quarter.

The sharp increase in net profit is mainly due to a one-off receipt of Rs 350 crore from Celgene, pursuant to settlement agreement related to Revlimid brand capsules in Canada.

The pharmaceutical company’s consolidated revenue for the June quarter, meanwhile, climbed by a tepid 3% to Rs 3,844 crore compared with Rs 3,721 crore a year ago. A CNBC TV18 poll was expecting Dr Reddy’s to post revenue growth of around 10%.

Global generics revenue, which contributed little over 80% to the total income, grew 8% to Rs 3,298.2 crore. Revenue from emerging markets grew 10% to Rs 730 crore, with much of that accruing from Russia (5%). North America, which is largely the US generics business, grew 3% to Rs 1,632.2 crore.

Sales from India business grew 15% to Rs 700 crore in the June quarter, mainly driven by volume traction and improved realizations in base business and new product launches.

“This quarter, we grew most of our key markets and hope to continue this momentum with a sharper focus on performance,” said G.V. Prasad, co-chairman and CEO at Dr. Reddy’s. “We will continue our journey of operational excellence, cost leadership and innovation across our businesses,” Prasad added.

Among other metrics, the company’s gross margins fell to 51.7% in the June quarter compared with 52.45% in the preceding March quarter and 55.7% in the year-ago quarter.

Dr Reddy’s Laboratories stock had already closed Monday’s trading session lower by 1.9% before the quarterly results were announced. The real effect of the earnings on the stock price would only be visible on Tuesday.

Meanwhile, Dr Reddy’s Laboratories also informed stock exchanges that Erez Israeli has been promoted as the company’s new chief executive officer (CEO) with effect from 1 August. GV Prasad will continue as co-chairman and managing director and Israeli will continue to report to him.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Subscribe to Moneycontrol Pro and gain access to curated markets data, trading recommendations, equity analysis, investment ideas, insights from market gurus and much more. Get Moneycontrol PRO for 1 year at price of 3 months. Use code FREEDOM.

Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwitterskypewhatsapp
Most Active
Company Price Change %Gain
Yes Bank 59.25 5.24
Indiabulls Hsg 467.85 3.84
Reliance 1,275.85 2.33
HDFC Bank 2,162.70 -0.52
ICICI Bank 395.40 -0.93
Company Price Change %Gain
Yes Bank 59.25 5.24
ICICI Bank 395.75 -0.85
Indiabulls Hsg 467.90 4.00
Bajaj Finance 3,175.35 1.85
Reliance 1,275.95 2.36
Top Gainers
Company Price Change %Gain
Zee Entertain 351.15 6.75
Vedanta 137.40 6.47
UPL 547.25 5.64
Yes Bank 59.25 5.24
BPCL 329.35 5.22
Company Price Change %Gain
Vedanta 137.50 6.55
Yes Bank 59.25 5.24
ONGC 122.30 4.66
M&M 533.10 4.09
Coal India 188.05 4.07
Top Losers
Company Price Change %Gain
IndusInd Bank 1,310.50 -1.88
ITC 236.10 -1.65
ICICI Bank 395.40 -0.93
Eicher Motors 15,383.45 -0.90
HUL 1,860.00 -0.65
Company Price Change %Gain
IndusInd Bank 1,310.35 -1.90
ITC 236.00 -1.71
ICICI Bank 395.75 -0.85
Power Grid Corp 201.40 -0.69
HUL 1,859.35 -0.69

Live TV

Loading...
Countdown To Elections Results
To Assembly Elections 2018 Results